CRP and psoriatic arthritis: To explore the hypothesis that remission induced by TNFi plus MTX in patients with early psoriatic arthritis can be sustained after withdrawal of TNFi, we conducted an open-label extension study of this trial with patients that were in DAS-CRP remission at week 22 and continued on MTX monotherapy.